{"entity":{"id":"nct06667544","kind":"trial","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","aka":["TRIAD1"],"tldr":"A phase 1/2 trial of RNK08954-01 in sarcomas, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.","summary":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation is a phase 1/2 interventional study registered as NCT06667544 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 152 participants planned, started 2024-11-08 and due to reach its primary completion in 2026-12. Interventions recorded: RNK08954-01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06667544","url":"https://clinicaltrials.gov/study/NCT06667544"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["ranok-therapeutics-hangzhou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06667544","phase":"1/2","setting":"A Phase 1/2, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of RNK08954 in Patients With Advanced Solid Tumors With a KRAS G12D Mutation TRIAD1 (Trial of RNK08954 In KRAS G12D Mutation)","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","started":"2024-11-08","startedType":"actual","enrolled":152,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06667544/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/"}]}}